Stay up to date with news and events
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
August 29, 2022
Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by…
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
August 10, 2022
The VIBRANT-HD study began in early 2022 and was a long-awaited trial of a huntingtin-lowering drug, branaplam, that could be taken by mouth. On Monday,…
Updates from uniQure about their gene therapy for Huntington’s disease
July 7, 2022
uniQure is a company specializing in gene therapy, and they have been working on an experimental drug for Huntington’s disease (HD), called AMT-130, that is…
Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
June 21, 2022
Scientists have developed a new model that maps out the different stages of Huntington’s disease (HD) in detail. Using artificial intelligence approaches, the researchers were…
A new roadmap to track Huntington’s disease progression
June 17, 2022
For those who were following the live tweets from HDBuzz about the CHDI HD Therapeutics Conference or tuned in to the HDSA Convention, we may…